Literature DB >> 22326278

Overview of global regulatory toxicology requirements for vaccines and adjuvants.

Yuansheng Sun1, Marion Gruber, Mineo Matsumoto.   

Abstract

This paper provides an overview of the legislations and regulatory approaches currently applied to the nonclinical safety assessment of human preventive vaccine products in three ICH regions, i.e., the EU, USA, and Japan. Perspectives of the three regions with regard to the various types of toxicity studies currently considered to assess the nonclinical safety of preventive vaccines are compared and described in more detail than in published guidelines. In addition, the common issues and current challenges in nonclinical safety assessment of preventive vaccines are discussed.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22326278     DOI: 10.1016/j.vascn.2012.01.002

Source DB:  PubMed          Journal:  J Pharmacol Toxicol Methods        ISSN: 1056-8719            Impact factor:   1.950


  7 in total

Review 1.  Clinical vaccine development for H5N1 influenza.

Authors:  Christopher H Clegg; Joseph A Rininger; Susan L Baldwin
Journal:  Expert Rev Vaccines       Date:  2013-07       Impact factor: 5.217

2.  Development of COVID-19 therapies: Nonclinical testing considerations.

Authors:  Paul Baldrick
Journal:  Regul Toxicol Pharmacol       Date:  2022-05-21       Impact factor: 3.598

3.  A physiologically-based pharmacokinetic (PBPK) model of squalene-containing adjuvant in human vaccines.

Authors:  Million A Tegenge; Robert J Mitkus
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-08-04       Impact factor: 2.745

4.  Toxicity and Local Tolerance of a Novel Spike Protein RBD Vaccine Against SARS-CoV-2, Produced Using the C1 Thermothelomyces Heterothallica Protein Expression Platform.

Authors:  Yuval Ramot; Noam Kronfeld; Yakir Ophir; Nati Ezov; Sheli Friedman; Markku Saloheimo; Marika Vitikainen; Hanna Ben-Artzi; Avi Avigdor; Ronen Tchelet; Noelia Valbuena Crespo; Mark Emalfarb; Abraham Nyska
Journal:  Toxicol Pathol       Date:  2022-05-05       Impact factor: 1.930

5.  Comparison of Current Regulatory Status for Gene-Based Vaccines in the U.S., Europe and Japan.

Authors:  Yoshikazu Nakayama; Atsushi Aruga
Journal:  Vaccines (Basel)       Date:  2015-03-18

Review 6.  Application of "Systems Vaccinology" to Evaluate Inflammation and Reactogenicity of Adjuvanted Preventative Vaccines.

Authors:  David J M Lewis; Mark P Lythgoe
Journal:  J Immunol Res       Date:  2015-08-25       Impact factor: 4.818

Review 7.  Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs.

Authors:  Nikolai Petrovsky
Journal:  Drug Saf       Date:  2015-11       Impact factor: 5.606

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.